Eptinezumab not checked

H. Lundbeck A/S · Lu AG09221

FollowEvery change as it happens, and a Monday email
Stage
in the US · approved in the EU
Next date
Phase 3 trial completes
Trials
4 active
17 in total · 6 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
How it’s given
“Eptinezumab will be administered per dose and schedule specified in the arm.”In the company’s words, NCT04965675 on ClinicalTrials.gov
Tested for
Chronic Migraine in Children, Episodic Migraine, Migraine
Main trialPhase 3
“To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.”In the company’s words, NCT04965675 on ClinicalTrials.gov
Other names
Vyepti · Lu AG09221

Other drugs for Episodic Migraine

All 14 drugs for Episodic Migraine

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials17

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 26 Mar 2027 A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
Phase 3Recruiting 6 Jul 2027 A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
Phase 3Recruiting 30 Apr 2028 A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
Phase 4Terminated 17 Feb 2023 Real World Effectiveness of Eptinezumab in Participants With Migraine
Phase 4Completed 22 Oct 2024 A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache
Phase 4Completed 2 Sep 2026 A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications
Phase 3Completed 8 Jul 2020 A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine
Phase 3Completed 15 Jul 2021 A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive Treatments
Phase 3Completed 23 May 2022 Eptinezumab in Adults With Migraine and Medication Overuse Headache
Phase 3Completed 14 Jun 2023 Eptinezumab in Participants With Episodic Cluster Headache
Phase 3Completed 29 Jun 2023 A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH)
Phase 3Completed 8 Jun 2024 Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan
Phase 3Completed 1 Oct 2024 Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine
Phase 1Completed 20 Jul 2021 Safety, Tolerability and Pharmacokinetics of Eptinezumab in Healthy Chinese Subjects
Phase 1Completed 20 Oct 2022 A Study in Children and Young People With Migraine to Learn What the Body Does to Eptinezumab
Phase 2Ended not given CAT-Trial: CGRP monoclonal Antibody for Treatment of painful diabetic neuropathy: a double-blind, multicenter, placebo-controlled, international phase II clinical trial
Phase 4Authorised not given Exploring Eptinezumab: Unveiling Peripheral and Central Mechanisms of Action and Searching for Biomarkers of Patient Response (EUPHORIA Study)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Eptinezumab

Following is part of Solo: you see every change to Eptinezumab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in